Nisonger Child Behavior Rating Form

Nisonger Child Behavior Rating Form 76 items rated 0—3 2 prosocial and 6 problem behavior subscales 8—15 minutes P, T Aman et ah, 1996 Tasse et ah, 1996... 

Nisonger Child Behavior Rating Form Public domain, Michael Aman, Ph.D., The Nisonger Center, Ohio State University, 1581 Dodd Drive, Columbus, OH 43210-1257... 

Tasse, M.J., Aman, M.G., Hammer, D., and Rojahn, J. (1996) The Nisonger Child Behavior Rating Form age and gender effects and norms. Res Dev Disabil 17 59-75. 

If one accepts the position that the structure of mental illness may differ for young people with MR, then it is also reasonable to choose assessment instruments that are appropriate to that population. There are several tools that have been developed for parent and teacher ratings of patients with MR. Examples are the Aberrant Behavior Checklist, the Developmental Behaviour Checklist, the Nisonger Child Behavior Rating Form, and the Diagnostic Assessment of the Severely Handicapped (see Hurley et ah, 1998 Chapter 32, this volume). 

Recently, Janssen Pharmaceutica launched several studies of risperidone in children with borderline IQ or MR and a diagnosis of disruptive behavior disorder (usually oppositional defiant disorder or conduct disorder). To be admissible into the study, subjects needed to be 5 to 12 years old, inclusive, and score above 24 on the Conduct Problem subscale of the Nisonger Child Behavior Rating Form (NCBRF). One 6-week acute trial (n = 118) was conducted in the United States (Aman et al., in press), whereas the other n = 110) was based in Canada (Snyder et al., in press). The findings of the two studies were virtually identical, with... 

Risperidone was also effective and well tolerated in 118 children aged 5-12 years with subaverage intelligence and severely disruptive behavior in a 6-week, multicenter, double-blind, randomized trial (7). Risperidone produced significantly greater improvement than placebo on the conduct problem subscale of the Nisonger Child Behavior Rating Form from week 1 (respective reductions in score of 15 and 6). The most common adverse effects of risperidone (mean dose at end-point 1.16 mg/day) were headache and somnolence the extrapyramidal symptom profile of... 

---